A wide variety ofantibodies reacting with nuclear and cytoplasmic antigens has been found in the serum of patients with systemic lupus erythematosus (SLE). There is, however, considerable evidence that the DNA/anti-DNA system is the most important of all recognized immune systems involved in the pathogenesis of lupus nephritis (Koffier and Kunkel, 1968; Cochrane and Koffler, 1973) . Furthermore, a close correlation has been shown between high titres of anti-DNA antibody and clinically active renal disease (Casals, Friou, and Myers, 1964) . In a long-term study ofpatients with lupus glomerulonephritis, those patients with persistently raised titres of anti-DNA antibody, which presumably reflects persistently active disease, would be expected to have a clinical course characterized by progressive renal impairment. If this hypothesis is correct then serial determinations of anti-DNA antibody titres would be of prognostic significance, and it would be necessary to analyse serial anti-DNA antibody titres in a large group of patients with a similar renal lesion, treated with the same modality, but following two different clinical courses. Previous reports, however, either have studied heterogeneous groups in which random samples were correlated with clinical activity (Casals and others, 1964; Schur and Sandson, 1968) or have studied serial changes in a few patients correlating anti-DNA antibody titres with exacerbations and remission of disease (Hughes, Cohen, and Christian, 1971) . The above hypothesis has therefore not yet been substantiated.
The present study correlates anti-DNA antibody titres, expressed as the DNA-binding capacity of serum (DNA-bc) with the long-term clinical course in 21 patients with proliferative lupus glomerulonephritis, treated with azathioprine and prednisone. It was also possible to determine whether DNA-bc titres provide a useful early index of disease activity.
Materials and methods

PATIENTS
Twenty-one patients between 8 and 34 years of age, followed by the Nephrology Section of the Department of Medicine and Pediatrics at Yale University School of Medicine, were available for study. All fulfilled the preliminary criteria for the classification of systemic lupus erythematosus as proposed by the American Rheumatism Association (Cohen, Reynolds, Franklin, Kulka, Ropes, Shulman, and Wallace, 1971) . Each patient was treated with azathioprine (2-3 mg/kg per d) and prednisone in a dose (average range 10-20 mg/d) sufficient to control extrarenal manifestations of the disease.
At the time of initial evaluation and at intervals of at least 6 months during treatment the following investigations were made. Blood urea nitrogen (BUN), serum creatinine, total serum protein, albumin/globulin ratio, and quantitative protein excretion. The renal histopathological diagnosis in all patients was established at the time of initial evaluation by renal biopsy. All cases selected for this analysis showed a proliferative glomerulonephritis and subendothelial electron-dense deposits. At the time this study was completed, follow-up ranged from 13 months to 6 years, with a mean observation period of 36 months. At the end of follow-up patients were classified as having either a favourable or unfavourable clinical course. Patients were placed in the favourable category at end of follow-up if serum creatinine was <132-6 ,umol/l (1-5 mg/100 ml) and urinary protein excretion was reduced or stable. Patients were classified as having an unfavourable course when serum creatinine was >132-6 pmol/l (>,15 mg/100 ml) and/or quantitative protein excretion increased by 1 0 g/d or more.
Serum samples obtained from these patients at various intervals between 1968 and 1973 were analysed for DNA-bc. Sera stored at -20°C was thawed overnight at 4°C before determination. Control samples were obtained from 100 healthy blood bank donors, 21 patients with seropositive rheumatoid arthritis, and 19 patients with rheumatoid variants, i.e., ankylosing spondylitis, Reiter's syndrome, and seronegative RA.
DNA-BINDING CAPACITY DNA-bc was determined by the ammonium sulphate technique as modified by Pincus, Schur, Rose, Decker, and Talal (1969) . Tritium-labelled E. coli DNA was kindly supplied by Dr. N. Rothfield (Luciano and Rothfield, 1973) .
DNA-bc was determined by the addition of0 1 p,g DNA in 50 p1 borate sodium chloride buffer (0-15 mol/l, pH 8 0) to 50 ,ul of a 1:10 solution of unheated serum in the same buffer. The mixture was incubated for one hour at 37°C and then overnight at 40C. Saturated ammonium sulphate solution (SAS) 100 ,u1 was added while the mixture was vigorously agitated on a Vortex stirrer because inadequate mixing of the heavy SAS and less dense serum solution could cause marked variation of results in duplicate samples as previously noted by Farr (1958) . The resulting 50% saturated mixture was maintained at 4°C for one hour and then centrifuged at 12000 g for five minutes to sediment the precipitate. 100 ,1 of the supernatant fraction (S) was then transferred to a liquid scintillation counting vial and 0-9 ml distilled water added. The remaining 100 ,ul (R) which contained both supernatant and precipitate was dissolved in 300 ul water and pooled with two 300 ul washes of distilled water in a second counting vial. Phase Combining System liquid (PCS 8-5 ml) and 0 5 ml NCS Solubilizer (AmershamSearle) were then added to each counting vial and the radioactivity of both S and R fractions determined in a liquid scintillation counter (Beckman). DNA-bc was calculated as a percentage of total radioactivity according to the formula: 100 x (R-S)/(R + S).
Determinations on duplicate samples almost always agreed to ±5 % of their mean but the test was repeated when greater disparity occurred.
Results
DNA binding capacity for serum samples from aormal controls, patients with rheumatoid arthritis, rheumatoid variants, and SLE is shown in Fig. 1 (Fig. 3) . In contrast to patients with type A pattern, DNA-bc levels in the group with type B were either consistently greater than 7000 for 10 months or more after beginning treatment (Fig. 3a) or fluctuated widely with marked increases at frequent intervals (Fig. 3b) Course of a patient whose type A pattern changed after azathioprine was discontinued. DNA-binding capacity of the serum rose 6 months before there was clinical evidence of deterioration (see text). Conversion: Traditional to SI units-C3: 1 mg/100 ml 0 01 g/l; serum creatinine: I mg/100 ml 88-4,umol/l. predominantly membranous pattern and subepithelial and intramembranous deposits. To this point the DNA binding pattern was typical of type A, and correlated with marked clinical improvement. Azathioprine was then discontinued and the patient maintained on prednisone 10 mg/day. Six months after discontinuing azathioprine, DNA-bc rose sharply to 780% and remained raised for 8 months (type B), while C3 levels decreased and remained low. However, it was not until 6 months after the rise in DNA-bc that the first clinical manifestations of active renal disease became apparent when proteinuria reappeared. A third renal biopsy showed a severe proliferative glomerulonephritis with massive subendothelial and mesangial deposits. DNA-bc levels fell at the time severe renal failure occurred.
Discussion
To examine the correlation between changes in levels of DNA antibody with the long-term course of patients with lupus nephropathy, serial changes in DNA-bc were estimated in 21 patients with proliferative lupus glomerulonephritis during treatment with prednisone and azathioprine. This group of patients was of special interest since this renal histological lesion is usually associated with a poor prognosis (Baldwin, Lowenstein, Rothfield, Gallow, and McClusky, 1970; Hayslett, Kashgarian, Cook, and Spargo, 1972) . In the present series approximately two-thirds of the patients improved while one-third deteriorated. It was therefore possible to analyse changes in DNA-bc in patients with a similar renal lesion, treated with the same medications, following two different clinical courses.
The ammonium sulphate technique used in this study was shown to be a sensitive and specific method for the detection of antibodies to DNA (Pincus and others, 1969) . DNA-bc values from normal controls and patients with rheumatoid disease in the present study were similar to those found by others (Pincus and others, 1969; Hughes, 1971) .
Analysis of these data show that the initial determination of binding capacity does not always correlate with severity of renal injury. At the time of the initial renal biopsy levels less than 40 % binding were found in 8 of 21 patients despite severe histological changes characterized by a proliferative glomerulonephritis and subendothelial deposits. Furthermore, the magnitude of the initial DNA-bc determination had no prognostic significance with regard to the final outcome. This seemed evident from the satisfactory progress of five patients whose initial DNA-bc exceeded 85 % but decreased after starting therapy and remained low for 30 months or more (see Fig. 2b ). (Hahn, Bagby, Hamilton, and Osterland, 1973) .
A persistently high DNA-bc level preceded the evidence of renal deterioration obtained by conventional renal function tests by as much as 10 months. Persistently raised DNA-bc may therefore indicate active disease which is not clinically apparent.
There was a sharp decline in binding capacity in six of eight patients with the onset of severe renal failure. Harbeck, Bardana, Kohler, and Carr (1973) noted a similar drop in DNA-bc in one patient when circulating immune complexes were present. Although this study did not examine the mechanism of this change, it is possible that release oflarge amounts of DNA bound the available circulating antibody. Whatever the explanation it is clear that under these circumstances low DNA-bc reflected severe exacerbation of disease rather than improvement. An accurate interpretation of these changes was only possible in light ofthe pre-existing pattern ofDNA-bc.
The present study shows that the persistence and magnitude of anti-DNA antibody titres could be correlated with the clinical course in 21 patients with lupus nephropathy. The important implication derived from these data is that serial measurement of DNA-bc may serve as a useful guide in the management of lupus glomerulonephritis. As suggested by Epstein and Grausz (1974) , it is probably the time of starting therapy rather than the use of a particular agent that favourably influences the prognosis. Therefore, in a patient with SLE and proliferative glomerulonephritis whose pattern of DNA-bc is known, it may be beneficial to modify treatment on the basis of serological parameters if significant changes persist for 3 consecutive months, such treatment being limited to patients with documented proliferative lupus glomerulonephritis only and not including all patients with SLE. It remains to be seen whether the addition of earlier and more aggressive therapy can prevent the development of the irreversible renal damage which occurred in several of our patients. 
